<DOC>
	<DOCNO>NCT02660827</DOCNO>
	<brief_summary>This study single-arm , multi-center , Home Hotel Clinical Investigation pediatric subject type 1 diabetes insulin pump therapy . The purpose study demonstrate close loop algorithm build 670G insulin pump safe part overall system .</brief_summary>
	<brief_title>Safety Evaluation Hybrid Closed Loop ( HCL ) System Pediatric Subjects With Type 1 Diabetes</brief_title>
	<detailed_description>The study proceed follow : Run-in Period - General : A total 120 subject ( age 7-13 ) enrol 10 investigational center ( 9 US , 1 Europe , Middle East Africa ( EMEA ) region ) order reach 80 subject complete HCL study . Study Period - At Home : Following two week run-in period use Study Pump ( 670G ) , subject participate 3-month study period . Study Period - Hotel Study Subjects participate Hotel study ( 6 day , 5 night ) , remainder study period spend home . Continued Access Program Subjects give opportunity extend use study device period 2 year . If subject choose participate continuation period , retain study device end study period visit receive back event return study staff already .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>General Inclusion Criteria 1 . Subject age 213 year time screen 2 . Subject clinical diagnosis type 1 diabetes 1 year determine via medical record source documentation individual qualify make medical diagnosis Studyspecific inclusion criterion 3 . Subject must minimum daily insulin requirement ( Total Daily Dose ) &gt; 8 unit 4 . Subject parent ( ) /guardian ( ) willing participate overnight visit end runin period . 5 . Subject 713 year age parent ( ) /guardian ( ) willing participate hotel study specify duration hotel stay . 6 . Subject 26 year age parent ( ) /guardian ( ) willing participate extend visit study period perform Frequent Sample Testing . 7 . Subject 26 year age willing able sensor insert abdomen per investigator discretion . 8 . Subject must companion 18 year old sleep dwell place every night study period . This requirement may verify subject report screen visit . 9 . Subject willing perform ≥ 4 finger stick blood glucose measurement daily 10 . Subject willing perform require sensor calibration 11 . Subject willing wear system continuously throughout study 12 . Subject Glycosylated hemoglobin ( A1C ) value le 10.0 % ( processed Central Lab ) time screen visit Note : All HbA1C blood specimen send test NGSP certified Central Laboratory . A1C test must follow National Glycohemoglobin Standardization Program ( NGSP ) standard . 13 . Subject TSH normal range OR TSH normal reference range Free T3 within lab 's reference range Free T4 within normal reference range . 14 . Pump therapy great 6 month prior screen ( without CGM experience ) 15 . Subjects parent ( ) /guardian ( ) willing upload data study pump ; must Internet access computer system meet requirement upload study pump 16 . If subject celiac disease , adequately treat determined investigator 17 . Subjects parent ( ) /guardian ( ) willing take one follow insulin financially support use either 2 insulin preparation throughout course study ( i.e . copayments insulin insurance able pay full amount ) Humalog® ( insulin lispro injection ) NovoLog® ( insulin aspart ) 18 . Subjects parent ( ) /guardian ( ) /companions must able speak literate English verify investigator 1 . Subject history 2 episode severe hypoglycemia , result follow 6 month prior screen : 1 . Medical assistance ( i.e . Paramedics , Emergency Room ( ER ) Hospitalization ) 2 . Coma 3 . Seizures 2 . Subject unable tolerate tape adhesive area sensor placement 3 . Subject unresolved adverse skin condition area sensor placement ( e.g. , psoriasis , dermatitis herpetiformis , rash , Staphylococcus infection ) 4 . Females sexually active able conceive exclude use effective method contraception agree continue use effective method contraception duration study determine investigator . 5 . Subject cardiovascular condition investigator determines exclude subject , i.e . ventricular rhythm disturbance , hypertrophic cardiomyopathy 6 . Subject treat hyperthyroidism time screen 7 . Subject diagnosis adrenal insufficiency 8 . Subject DKA 6 month prior screen visit . 9 . Subject take oral , injectable , intravenous ( IV ) glucocorticoid within 8 week time screen visit , plan take oral , injectable , IV glucocorticoid course study 10 . Subject actively participate investigational study ( drug device ) wherein he/she receive treatment investigational study drug investigational study device last 2 week 11 . Subject hospitalize visit ER 6 month prior screen result primary diagnosis uncontrolled diabetes 12 . Subject currently abuse illicit drug 13 . Subject currently abuse marijuana . 14 . Subject currently abuse prescription drug 15 . Subject currently abuse alcohol 16 . Subject use pramlintide ( Symlin ) , DPP4 inhibitor , liraglutide ( Victoza GLP1 agonist ) , metformin , canagliflozin ( Invokana SGLT2 inhibitor ) time screen 17 . Subject history visual impairment would allow subject participate study perform study procedure safely , determine investigator 18 . Subject elective surgery plan require general anesthesia course study 19 . Subject sickle cell disease , hemoglobinopathy ; receive red blood cell transfusion erythropoietin within 3 month prior time screen 20 . Subject plan receive red blood cell transfusion erythropoietin course study participation 21 . Subject diagnose current eating disorder anorexia bulimia 22 . Subject diagnose chronic kidney disease result chronic anemia 23 . Subject hematocrit normal reference range lab use . 24 . Subject dialysis 25 . Subject serum creatinine &gt; 2 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>